Company profile: Sitryx
1.1 - Company Overview
Company description
- Provider of cell metabolism–targeted, first-in-class, disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Pipeline includes SYX-5219 for atopic dermatitis; SIT-052, an inhaled GLS1 inhibitor for pulmonary fibrosis and COPD that selectively breaks down senescent cells; SIT-033, a SIK2 inhibitor for ulcerative colitis; and SYX-1042 and SIT-047 for autoimmune indications (with Eli Lilly).
Products and services
- SIT-033: An isozyme-selective SIK2 inhibitor for ulcerative colitis that precisely targets SIK2 to maximize efficacy and therapeutic index
- SIT-052: An inhalation-delivered GLS1 inhibitor for pulmonary fibrosis and COPD that selectively breaks down senescent cells to reduce fibrosis and inflammation
- SYX-5219: An immune-modulating pyruvate kinase M2 activator for atopic dermatitis that modulates B and T lymphocyte activity to reduce skin inflammation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sitryx
Valenza Biotech
HQ: United States
Website
- Description: Provider of biomarker-driven therapeutic development for autoimmune and inflammatory diseases, leveraging monoclonal antibodies that target surface antigens to reduce pathogenic subpopulations of autoreactive cells, guiding research and clinical development toward safe and effective treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valenza Biotech company profile →
Cyxone
HQ: Sweden
Website
- Description: Provider of biopharmaceutical R&D focused on cyclotide-based drugs for severe autoimmune diseases. Operates via an international expert network across research, development and manufacturing. Pipeline includes Rabeximod, an oral Phase 2 candidate for rheumatoid arthritis targeting inflammatory macrophages, and T20K, an early clinical candidate for multiple sclerosis modulating T cell activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyxone company profile →
BioAtla
HQ: United States
Website
- Description: Provider of conditionally active biologics (CABs) for cancer-targeted therapeutics activated under specific physiological conditions; the CIAO! platform for antibody optimization; CAB-ADCs, CAB-CAR-T, and CAB-Bispecifics to improve safety and efficacy; and Mecbotamab Vedotin, a CAB-AXL-ADC for AXL-expressing tumors evaluated in sarcoma and NSCLC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAtla company profile →
Phenex Pharmaceuticals
HQ: Germany
Website
- Description: Provider of drug discovery and development focused on novel pharmaceuticals, leveraging small-molecule expertise. Privately held, founded in 2002, with Biology and Chemistry laboratories and offices in the Biotech Cluster Rhine-Neckar, primarily in Heidelberg and partly in Ludwigshafen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phenex Pharmaceuticals company profile →
Nuvig Therapeutics
HQ: United States
Website
- Description: Provider of therapies that induce natural mechanisms to restore immune homeostasis, including NVG-2089, a recombinant, non-immunosuppressive immunomodulator targeting type II Fc receptors to reduce autoimmune dysregulation, in clinical development for inflammatory myopathies and dermatologic autoimmune diseases; recombinant proteins activating immune regulatory receptors; and engineered therapeutic antibodies for autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvig Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sitryx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sitryx
2.2 - Growth funds investing in similar companies to Sitryx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sitryx
4.2 - Public trading comparable groups for Sitryx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →